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ABSTRACT 
The debate about the best approach to select patients with hepatocellular cancer (HCC) waiting for 
liver transplantation (LT) is still ongoing. This study aims to identify the best variables allowing to 
discriminate “high-” and “low-benefit” patients. To do so, the innovative concept of intention-to-
treat (ITT) survival benefit of LT has been created. Data of 2103 adult HCC patients consecutively 
enlisted during the period 1987-2015 were analyzed. Three rigorous statistical steps were used in 
order to create the ITT survival benefit of LT: the development of an ITT LT and a non-LT survival 
model, and the individual prediction of the ITT survival benefit of LT defined as the difference 
between the median ITT survival with (based on the first model) and without LT (based on the 
second model) calculated for each enrolled patient. Four variables (MELD, alpha-fetoprotein, 
Milan-Criteria status and radiological response) displayed a high effect in terms of delta-benefit. 
According to these risk factors, four benefit groups were identified. Patients with three-four factors 
(“no-benefit group”, n=405/2103; 19·2%) had no benefit of LT compared to alternative treatments. 
Inversely, patients without any risk factor (“large-benefit group”, n=108; 5·1%) yielded the highest 
benefit from LT reaching 60 months. Conclusion: The here presented innovative ITT transplant 
survival benefit allows to better select HCC patients waiting for LT. The obtained stratification may 
lead to an improved and more equal way for organ allocation. Patients with no benefit should be de-
listed, whilst patients with large benefit ratio should be prioritized for LT.  
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INTRODUCTION 
The debate about the best approach for selecting patients with hepatocellular cancer (HCC) waiting 
for liver transplantation (LT) is still ongoing. Recent literature has shown that outcome of HCC 
patients in which the selection for LT is based on specific restrictive tumor characteristics may 
generate survival rates comparable to those obtained after LT in non-HCC patients. Furthermore, 
LT may also represent an optimal treatment for HCC patients harboring tumors being out of 
conventional (Milan) criteria if morphological and biological tumor behavior is taken into account.
1
 
Consequently, the line between the need to justifiably transplant as many patients as possible and 
the necessity to select only patients having an effective benefit from LT is very thin and represents 
therefore an everyday clinical challenge.  
Recently, the concept of “transplant benefit”, corresponding to the number of years gained by LT 
minus the number of years offered by alternative treatments, has been proposed in the field of liver 
transplantation.
2
 In the context of non-HCC patients, the concept of transplant benefit has been 
efficaciously adopted. Indeed, patients with a model for end-stage liver disease (MELD) score <15 
do not improve their survival if transplanted or if staying on the waiting list (WL).
2
 When follow-up 
period is no longer than 10 years, transplant benefit estimation is equally influenced by pre- and 
post-LT variables, thus providing a balance between the concepts of pure urgency (“the sickest 
first”) and pure utility (the highest survival gain).
3
  
However, the definitive answer on the best pre- and post-LT variables to be used for selecting HCC 
patients able to reach an effective benefit from LT is still needed. Apart from morphological 
aspects, biological and “time-dependent” variables have been recently added in the LT selection 
process.
4
 Among them, waiting time (WT), alpha-fetoprotein (AFP) values and radiological 
response after neo-adjuvant loco-regional treatment (LRT) have been largely explored.
5–9
  
Moreover, transplant benefit values have been always evaluated from the moment of LT and not 
from the moment of WL inclusion. In the present study, the innovative concept of intention-to-treat 
(ITT) transplant benefit has been proposed. ITT survival is defined as the LT survival from the 
Page 5 of 42
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Lai Q et al. INTENTION-TO-TREAT SURVIVAL…       5 
 
moment of patient enlistment and not from the day of LT,
10
 having been widely accepted in the LT 
community.
11,12
 The use of an ITT survival analysis allows the opportunity to analyze the results 
based on the initial treatment assignment and not on the treatment eventually received, thus 
avoiding various misleading artifacts and initial selection biases. 
The aim of the present study is then to analyze a large multicenter European collaborative Project, 
with the intent to identify the best variables able to discriminate high or low benefit patients. In 
order to do so, an ITT survival benefit has been developed, aiming at identifying different patient 
subgroups deserving or not LT.  
 
MATERIALS AND METHODS 
A retrospective analysis of data from 2103 adult (≥18 year-old) patients with radiological and/or 
pathological diagnosis of HCC was performed. All patients were listed for LT during the period 
from January 1, 1987 to December 31, 2015, and being dropped-out or undergoing a first LT during 
the same time period. Data were obtained from the prospectively collected databases of ten 
collaborative European Centers involved in the EURopean HEpatocellular CAncer and Liver 
Transplantation (EurHeCaLT) Project. The participating centers were Padua, Italy (n=346); 
Brussels, Belgium (n=336);  Innsbruck, Austria (n=330); Sapienza University Rome, Italy (n=243); 
Royal Free London, UK (n=193); Mainz, Germany (n=176); San Camillo Hospital Rome, Italy 
(n=142); Tor Vergata University Rome, Italy (n=140); Ancona, Italy (n=110); and, Catholic 
University Rome, Italy (n=87). 
Patients with incidental tumors, mixed hepatocellular-cholangiocellular tumors or cholangiocellular 
cancer misdiagnosed as HCC were excluded from the analysis.  
Of note is that all of the participating centers do not consider anymore Milan Criteria (MC) as the 
limit for inscription on the WL: consequently, 636 (30·2%) MC-OUT patients were enlisted. 
Despite different policies were used in the different centers, all the transplanted cases reported were 
within University of San Francisco California Criteria, Up-to-seven Criteria or Tokyo (“5+10 role”) 
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Criteria: so, the dimensional upper limit observed in the present study was 6.5 cm of diameter in the 
target lesion and 10 nodules. A majority of patients (n=1754; 83·4%) had pre-LT multimodal LRT. 
Such policy allowed an in-depth analysis of the response to LRT as a possible selection variable. 
All analyzed patients were categorized in different groups according to the modified Response 
Evaluation Criteria in Solid Tumors (mRECIST) criteria termed as Complete Response (CR), 
Partial Response (PR), Stable Disease (SD) and Progression Disease (PD).
10
 Patients which did not 
have LRT were considered as no-LRT group: the decision to not consider no-LRT patients with a 
possible increase of the tumor burden before LT into the PD group derived from the consideration 
that these patients do not fully correspond from a biological point of view to patients with a tumor 
with a PD after a radiological treatment. In the treated patients, mRECIST status was defined after 
comparison between initial imaging at WL inscription and the last available one before LT or drop-
out (DO). 
Patients listed before 1996 and 2010 were re-classified according to MC and mRECIST criteria 
according to the retrospective evaluation of their imagings.
1,13 
The adopted cut-offs of 1000 ng/mL and 15 ng/mL/month for AFP and AFP slope were selected 
according to literature data.
6,7
 The AFP slope was calculated using the two values at the moment of 
WL inscription and the one immediately before LT or DO. The adopted WT cut-off of 120 days and 
MELD cut-off of 13 were also chosen according to previous reports.
5,11,14
  
Median patient follow-up (FU) from the moment of WL inscription was 3.7 years (interquartile 
ranges [IQR]: 1.4-7.6).  
 
Statistical analysis 
Continuous variables were reported as medians and IQR. Dummy variables were reported as 
numbers and percentages. Missing data relative to study covariates always involved less than 10% 
of patients. Thus, they were estimated using the Maximum Likelihood Estimation method.
15 
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The statistical design of this study included three main steps: a) the development of an ITT LT 
survival model; b) the development of a non-LT survival model and; c) the individual prediction of 
the ITT survival benefit of LT defined as the difference between the median ITT survival with LT 
(based on the first model) and median survival without LT (based on the second model) calculated 
for each enrolled patient. The specific steps for the construction of the models are diffusely 
explained in Supplementary Data 1. We briefly reported here the statistical steps we adopted.  
Firstly, the ITT LT survival model was constructed using a log-logistic model: the results of the 
model are reported in Supplementary Table 1. The obtained results of the model were applied to 
predict ITT median survival with LT of each enrolled patient. 
Non-LT survival model was built starting from some assumptions: the majority of WL patients are 
censored by LT;
16,17
 median WT of HCC patients is relatively short, thus prediction of long-term 
survival of these patients may be inaccurate.
5
 Several statistical techniques have been proposed for 
resolving this problem.
16-18
 However, these methods are still insufficient to resolve the biases 
related to the complexity of WL dynamics, often requiring arbitrary corrections.
18,19
 The Model to 
Estimate the Survival In Ambulatory patients with HCC (MESIAH) was then adopted for resolving 
this problem.
14
 This model, recently validated both in western and eastern countries, 
20,21
 provides a 
simple formula to translate the MESIAH score in individual survival predictions. Using patient 
characteristics at the last evaluation before LT or DO, we used the MESIAH score to simulate the 
median time to death that patients censored by LT would have had in the absence of LT. This 
simulated time to death was therefore used to perform a second log-logistic parametric survival 
model to find significant predictors of non-LT survival: the results of the model are reported in 
Supplementary Table 2. Then, we used this second model to predict non-LT median survival of 
each enrolled patient. 
Finally, The ITT LT and the non-LT survival log-logistic models generated two median survival 
predictions for each enrolled patient. The ITT survival benefit of LT was, therefore, calculated for 
each patient as the difference between ITT LT median and the non-LT median survival estimations. 
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All estimations were capped at 120 months, since this time horizon represents the ideal balance 
between utility and urgency allocation principles.
4
 A multivariate least square regression was finally 
used to find significant predictors of ITT LT benefit among studied variables.
22,23
 In all the 
multivariable survival models, all variables with p<0.1 at univariate model were included. In the 
final model only variables showing a significant impact on survival at the first multivariable model 
were maintained. 
Since p-values can be biased from population size, results of survival benefit estimations in 
covariates subgroups were reported as effect size. Effect size is a standard measure that can be 
calculated from any number of statistical outputs. One type of effect size, the standardized mean 
effect, expresses the mean difference between two groups in standard deviation units. Typically, it 
is reported as Cohen's d, or simply referred to as d-value.
24 
Variables with a p<0.05 were considered statistically significant. The calculations were done with 
the JMP (1989–2003 SAS Institute Inc.) and Stata/IC 13.0 (1985-2013 StataCorp LP) packages. 
 
RESULTS 
Demographics of the entire population are displayed in Table 1. Two hundred forty-six (11·7%) of 
2103 patients dropped-out during the WT period: 160/246 (65·0%) cases dropped-out due to HCC 
progression, with 143/246 (58·1%) patients dying during the WT period. Looking more in detail the 
reasons of DO, 69 patients were excluded due to HCC progression (patient alive at the moment of 
DO). In 91 cases, a tumor-related death on WL was observed; 52 patients showed a liver disease-
related death on WL, 25 moved to another center, and 9 were excluded due to poor compliance. 
A total of 1857 patients underwent LT: 242 (13·0%) patients recurred. When considering the 1504 
patients having a minimum FU of 1 year after LT, the recurrence rate was 16·1%.   
After the construction of the different models, a multivariate least square regression analysis finally 
identified eight variables as significant predictors for ITT transplant benefit. Five variables favored 
an increase of benefit: age at listing (β-coefficient=1·3; p-value=0·0006), MELD at LT or DO (β-
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coefficient=1·1; p-value<0·0001), WT duration (β-coefficient=0·1; p-value=0·001), last 
radiological HCC assessment of the major lesion diameter (β-coefficient=10·9; p-value<0·0001), 
and of number of HCC lesions (β-coefficient=6·5; p-value<0·0001). In other terms, a higher benefit 
was reported in older patients, if MELD or WT increased, or if greater tumors were transplanted.  
Three variables pointed towards a poor benefit: WL inscription before 2001 (β-coefficient=-25·3; p-
value<0·0001), mRECIST PD (β-coefficient=-36·8; p-value<0·0001), and last available logAFP 
value (β-coefficient=-3·4; p-value<0·0001). In other terms, being listed before 2001, presence of 
radiological PD and progressive increase in AFP values were all linked to a poor benefit (Table 2).  
ITT transplant benefit estimations in different clinically relevant subgroups were also looked at 
(Table 3). Five variables showed a moderate-to-high effect in terms of differences of median 
benefit: patients with last AFP value ≥1000 ng/mL (6·8 vs. 25·4 months in patients with AFP < 
1000 ng/mL; D-value=0·69), lab-MELD ≤13 (19·8 vs. 39·1 months in patients with MELD > 13; 
D-value=0·81), mRECIST PD (10·6 vs. 29·2 months in patients without PD; D-value=0·78) and 
mRECIST CR (7·2 vs· 28·7 months in patients without CR; D-value=0·90) had very disappointing 
benefits. MC-IN status (22·8 vs. 34·5 months in patients exceeding MC;  D-value=0·47) and WL 
inscription before 2001 (10·4 vs. 27·3 months in patients enlisted after 2001; D-value=0·49) 
presented only a moderate benefit discrimination (Table 3, Figure 1).  
Based on these results, it was firstly decided to exclude the period of transplantation from further 
analyses because it was considered as useless when applying to patients transplanted nowadays. 
When doing so, four benefit groups could be identified according to the presence of the remaining 
four risk factors. Patients presenting a combination of three to four factors (no benefit group: 
n=405/2103; 19·2%) had no benefit in being transplanted compared to alternative therapies (median 
value of improved survival: zero months). Patients in the small (two risk factors: n=897; 42·7%) 
and moderate (one risk factor: n=693; 33·0%) groups displayed improved survival benefits of 20 
and 40 months, respectively. Conversely, patients without any risk factor (large benefit group: 
n=108; 5·1%) had the highest benefit reaching 60 months (Table 3, Figure 2). Different contour 
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plots deriving from the combination of the different risk factors are displayed in Supplementary 
Figure 1. 
 
DISCUSSION 
Twenty years after its introduction, MC are not anymore considered to be the best criterion to select 
HCC patients for LT.
25
 However, the best compromise between the need to justifiably raise the 
number of transplantable patients and the necessity to minimize the risk for recurrence, without 
contemporaneously harming non-HCC patients on the WL, is still out.
19
  
Aiming at squaring the circle, a recent paper by Mazzaferro interestingly reported that the only way 
to frame the complex scenario of LT for HCC is the ability to capture in a weighty manner tumor 
evolution in relation to its treatment, aiming to modulate scores able to estimate the risk of pre-LT 
DO and post-LT benefit.
26
 So, morphology “per se” is insufficient to optimize selection and 
allocation, and new criteria, possibly focused on “progression” instead than on static tumor 
characteristics should be used in order to better identify those patients in real need for LT.
4
  
In Italy, a demanding effort has been made with the intent to build an algorithm based on the 
principles of urgency, utility and transplant benefit, clearly underlying the inequity of a purely 
MELD-based HCC allocation model. Different variables (response to LRT, WT, AFP) all have 
been advocated as possible selection criteria to be used in such a “benefit scenario”.
27
 However, the 
main limit of their use in the setting of benefit is that no scientific evidence exists on their effective 
contribution in terms of survival.  
In the present study, four different risk factors connected with poor ITT-benefit, have been 
identified: radiological progression/complete response, AFP increase, MC-IN status and low MELD 
score.  
Several previously published studies corroborate our findings. The recent paper by Metha reported a 
selected population of HCC T2 patients waiting for LT with a very low 2-year probability of DO 
(only 1·6%). Tumor morphology (1 tumor of 2-3 cm), radiological response to LRT (complete 
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response after the first treatment), and biological behavior (AFP level stably normal after the first 
LRT) selected these patients.
28 
Several European studies similarly confirmed the paramount role of radiological response,
8,9,11
 and 
AFP modification following LRT,
6,7,11,18
 as the better selection criterion of HCC patients awaiting 
LT. The multicentric EurHeCaLT study showed that the combination of radiological response and 
AFP slope allowed to better discriminate “low-risk” from “high-risk-for-recurrence” patients, and 
this independently from their MC-IN or OUT status.
12
. Two recent scores, all focusing on the HCC 
selection process, further underlined the importance of combining biology and morphology in order 
to further improve results. Interestingly, the TRAIN score, based on the combination of AFP slope, 
radiological progression, inflammatory markers and WT, was superior respect to MC in predicting 
patient death during the WT in a long-WT population, whilst it was superior in predicting post-LT 
recurrence in case of short WT.
11
 The MORAL score, incorporating inflammatory markers, AFP 
and tumor morphology, also showed to be significantly superior to MC, with an area under the 
curve of 0·82 vs. 0·63 for predicting post-LT HCC recurrence.
29
  
Also the fact that MC-IN status was connected with poor survival benefit had been observed in a 
multicentre Italian study including 1328 patients: survival benefit was obtainable in patients having 
advanced HCC, and this was regardless of the “nodule number-size criteria” (as MC are).
30
 In other 
terms, the benefit increases when the number of nodules and the dimensions of the tumor 
contemporaneously increase, on the condition that radiological findings and AFP do not progress.  
Various articles already focused on the role of MELD increase as a cause of increased benefit. A 
US study clearly observed that the increase in MELD points corresponds to a progressive survival 
benefit increase in HCC and non-HCC patients, ranging from just a few months in patients with 
MELD score of 6-8 to 4 years in patients with MELD score of 36-40.
19
 Another Italian study 
similarly reported that MELD score increase was associated with a better benefit both in HCC and 
non-HCC patients; interestingly enough, this study observed that an equation based on the 
combination of MELD and AFP (the “HCC-MELD” equation) allowed the calculation of a 
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numerical score for HCC patients, with the intent to calibrate their transplant benefit with the one 
observed in non-HCC patients having the same MELD value.
18
 This finding was also observed in 
the present series, in which MELD and AFP were factors allowing to discriminate low- and high-
benefit patients.  
Despite the fact that each risk factor has already been singularly investigated in other studies 
focusing on the prediction of survival in HCC patients, one should note that the present study 
presents several innovations. Firstly, a new concept of ITT survival benefit has been proposed, as 
well as a statistical methodology has been created for calculating it. The rationale for the proposal 
of this new concept is to further increase the balancing between pure priority and pure utility: the 
integration of two large populations of LT and non-LT patients in the creation of the ITT benefit 
statistical model allowed in fact to better calibrate the role of the evaluated variables in both 
settings.  
Secondly, radiological response to LRT has been investigated for the first time in a benefit-related 
analysis. The lack of studies investigating its role in the LT selection process may be explained by 
the fact that several large cohorts include a smaller number of LRT cases compared to our series; 
moreover, radiological response has not been systematically collected in large populations, so until 
now only small mono-centre studies (apart the reported EurHeCaLT study) have been 
investigated.
12
  
Thirdly, this is the first time that all of the investigated variables have been connected in order to 
create different ITT benefit groups, and to define categories of patients that would benefit from LT.  
In fact, when three to four of the analyzed risk factors are present in a single patient, ITT benefit 
was nil. Such a result is extremely important, because patients presenting three to four risk factors 
represented 19% of the investigated population. Interestingly enough, this specific “no benefit” 
group consisted of two main patient categories. On one side, MC-IN patients with low MELD 
showing radiological-biological progression were observed. These patients are similar to those 
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patients already reported in the study by Metha, in which poor radiological response and increased 
AFP corresponded to higher percentages of DO.
28
 
On the other hand, MC-IN patients with low MELD with complete radiological response 
corresponded to the Transplantable Tumor (TT)0 category reported by Mazzaferro, in which the 
cancer is “zeroed” by LRT/resection during the WT.
26
 In both scenarios such patients should be 
delisted: in the first case because of the poor benefit connected with an advanced cancer, in the 
second case due to a poor benefit associated with a completely healed tumor. 
Conversely, when looking at the “high” ITT benefit group, an extraordinary benefit (5 years) in 
comparison to not-transplanted patients presenting the same characteristics was observed. As a 
consequence, it looks obvious that such a patient population should be surely considered for LT. 
Despite the fact that this group consists of high-MELD MC-OUT patients (without any evidence of 
radiological-biological progression), thus potentially being associated with more peri-operative 
mortality and post-LT recurrence, the benefit in transplanting (and even prioritizing) them is clear. 
Moreover, it should be underlined that such a population is really small, representing no more than 
5% of the entire investigated population. Therefore, prioritization of such a population should only 
marginally impact on the number of used grafts, mainly if we consider on the opposite the great 
number of potentially “preservable” livers if we delist the patients with no ITT benefit (as a 
reminder, this group represents 19% of all the investigated cases!).  
When considering the group of patients presenting “low” ITT benefit (patients with two risk factors: 
20 months of benefit), one should keep in mind that the decision to transplant these patients has to 
be seen in the context of the opportunity to perform a LT without harming the group of listed non-
HCC patients (“concept of equity”).
31
 Such a concept has been very elegantly demonstrated by  
Volk in the US population, in which the decision to transplant an HCC patient was justified only if 
a minimal survival threshold was reached: only in this case, in fact, the benefit of transplanting 
tumor patients outweighed the harm for not transplanting non-HCC patients.
32
 Similar results were 
also reported in a monocentre experience from Italy.
33
 As a consequence, patients presenting only 
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small benefit (corresponding to 42·7% of our entire investigated population) should be carefully 
considered, mainly when evaluated in a low-volume center. As an example, a MC-OUT patient 
with low MELD and AFP ≥1000 ng/mL should be closely evaluated in a low-volume centre in light 
of his high recurrence risk.  
The present study did not explore the opportunity to propose a more equal organ allocation model 
among enlisted HCC and non-HCC patients in terms of priority score for LT,  such the “HCC-
MELD” model did.
18
 Moreover, this latter score is based only on AFP and MELD and it was 
calculated only in T2 HCC patients, whilst the present score presents a higher complexity (AFP, 
MELD, radiological response, initial MC status). The development of an equation able to 
recalibrate the whole allocation process (i.e. including both selection of patients for listing and 
prioritization of listed patients) among non-HCC and HCC patients should be further explored.  
The authors admit that the present study has some limitations. First of all, it is a retrospective 
collaborative non-randomized study covering 30-year period. Consequently, some statistical and 
methodological limits exist. However, we feel confident that the largeness of the investigated 
population and the rigorous adherence to the statistical analysis guidelines may have counteracted 
these negative parameters. Moreover, the introduction of the period of WL inscription as covariate 
in the multivariate models further minimizes the possible errors deriving from a “period-dependent” 
selection.   
Another possible limit derives from the fact that allocation disparities may be caused by not 
investigated parameters other than tumor characteristics (i.e., blood group): unfortunately, the 
retrospective character of the present study did not give the opportunity to fully investigate such 
aspects.
 
 
CONCLUSIONS  
The innovative ITT survival benefit of LT allows to better discriminate HCC patients waiting for 
LT in relation to their real need for transplantation. Such a stratification may lead to an improved 
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and more equitable liver allocation. New aspects such as radiological response after LRT should be 
implemented in clinical practice as a selection parameter to be used in HCC patients. The 
combination of radiological and biological tumor characteristics should be considered as the gold 
standard for HCC selection instead of the conventionally used “only morphological” criteria.  
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FIGURES 
Figure 1. Benefit risk factors and benefit gains. For each of the 9 reported risk factors (section A), 
two median benefits are reported according to specific threshold values (section B). Median benefit 
gains are calculated for each factor by difference between the reported median benefits (section C). 
Benefit gains are arbitrary grouped in 4 levels (very small, small, moderate and large benefit).  
 
Figure 2. Incidence of the 4 different “Benefit Groups” in the examined population.  
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            Brussels, 18 November, 2016 
 
 
Dear Editor, 
 
We hereby submit our original manuscript entitled “INTENTION-TO-TREAT SURVIVAL BENEFIT OF 
LIVER TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CANCER” 
 
We report a retrospective analysis of data coming from 2103 adult patients with hepatocellular cancer 
(HCC) enlisted for liver transplantation (LT) during the period 1987-2015. Data were obtained from the 
prospectively collected databases of ten collaborative European Centers involved in the EURopean 
HEpatocellular CAncer and Liver Transplantation (EurHeCaLT) Project. 
 
The present study, based on a sophisticated statistical analysis, introduces the innovative concept of 
intention-to-treat (ITT) survival benefit of LT. 
 
This new selection tool allowed to better select HCC patients waiting for LT. Four groups presenting 
different benefit gains were then identified, thus leading to an improved and more equal way for organ 
allocation. In fact, patients with no benefit ratio should be de-listed, whilst patients with large benefit ratio 
should be prioritized for LT. 
 
We are of the opinion that the present paper represents an added value to surgeons, oncologists, and 
mainly gastroenterologists and transplant physicians dealing with HCC and indication or prioritization for LT. 
 
All authors participated in the intellectual content, conception and design of the paper, took public 
responsibility for it and have agreed to have their name listed as contributors. Neither this manuscript nor 
parts of it have been previously submitted for publication. 
 
None of the authors received any financial interest, direct or indirect, related to the achievement of 
this work. 
 
If requested by the editors, we will provide the data and information on which the results of this 
manuscript are based.  
 
We hope that this paper can be accepted for publication in the HEPATOLOGY Journal. 
 
 
Sincerely Yours 
 
Quirino LAI, MD PhD 
 
Corresponding author 
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HEP-16-2270 
INTENTION-TO-TREAT SURVIVAL BENEFIT OF LIVER TRANSPLANTATION IN PATIENTS 
WITH HEPATOCELLULAR CANCER 
 
We thank the Editors of HEPATOLOGY for having the opportunity to revise the article with the intent to 
improve its quality. We hope the revision work will be able to fully satisfy the requests of the reviewers.  
 
 
Reviewer: 1 
 
We really thank the reviewer for the statistical suggestions and comments. To better answer to his/her 
issues, we have performed a complete statistical revision of our study with the help of an expert 
Statistician from Padua University. 
 
Lai et al. are proposing a transplant benefit model based on intention-to-treat (ITT) to assess the number 
of life years gained/lost by transplanting patients with HCC. They suggest that ideal candidate for 
transplant (with the highest transplant benefit) have high MELD (>13), reasonable AFP (<1000), no 
progressive disease/complete response, and are outside Milan. 
The concept is of interest, and represents a further adaptation from previous data. The proposed model 
cannot be considered as final, but it helps understanding the expected benefit from transplant in specific 
patients. The article is well written. 
 
 
1) One of the originality of the model is the ITT concept, and I would suggest better highlighting this 
point, by better explaining the current model versus previous ones (especially the one in Vitale et al. J 
Hepatology 2014). 
 
ANSWER. We thank the reviewer for this important comment giving us the possibility to better explain 
these important concepts. The following sentence has been added in the Introduction section of the paper: 
“Moreover, transplant benefit values have been always evaluated from the moment of LT and not from 
the moment of WL inclusion. In the present study, the innovative concept of intention-to-treat (ITT) 
transplant benefit has been proposed. ITT survival is defined as the LT survival from the moment of 
patient enlistment and not from the day of LT, having been widely accepted in the LT community. The use 
of an ITT survival analysis allows the opportunity to analyze the results based on the initial treatment 
assignment and not on the treatment eventually received, thus avoiding various misleading artifacts and 
initial selection biases.” 
Regarding to the model by Vitale et al., it was actually proposed with the intent to create a more equal 
organ allocation among enlisted HCC and non-HCC patients in terms of priority score for LT. The 
present study did not explore such an aspect, focusing on the detection of variables able to discriminate 
among high-benefit and low-benefit HCC patients and on the definition of the challenging clinical 
decision about the patients to include vs. to exclude from the WL. The “HCC-MELD” score proposed by 
Vitale et al. is based only on AFP and MELD and it was calculated only in T2 HCC patients, whilst the 
present score presents a higher complexity (AFP, MELD, radiological response, initial MC status).  
A sentence has been added in the Discussion section of the paper: 
“The present study did not explore the opportunity to propose a more equal organ allocation model 
among enlisted HCC and non-HCC patients in terms of priority score for LT, such the “HCC-MELD” 
model did. Moreover, this latter score is based only on AFP and MELD and it was calculated only in T2 
HCC patients, whilst the present score presents a higher complexity (AFP, MELD, radiological response, 
initial MC status). The development of an equation able to recalibrate the whole allocation process (i.e. 
including both selection of patients for listing and prioritization of listed patients) among non-HCC and 
HCC patients should be further explored.” 
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2) Please provide the number of missing data for each studied variable (potentially in Table 1). How were 
they handled? 
 
ANSWER. We really thank the reviewer for this comment because we actually forgot to specify one 
important aspect of our statistical analysis in the methods. 
“Missing data relative to study covariates always involved less than 10% of patients. Thus, they were 
estimated using the Maximum Likelihood Estimation method.”  
A reference was added accordingly: Baraldi AN, Enders CK. An introduction to modern missing data 
analyses. Journal of school psychology 2010; 48(1): 5-37. 
 
3) Figure 2 suggests that patients without LRT have no risk factor, yet they could still present a PD. 
Please explain and expand. 
 
ANSWER. We agree with the reviewer. However, when we defined PD or CR, we only considered the 
cases with an effective post-treatment radiological response accordingly to the mRECIST criteria. These 
criteria have been defined in accordance with the effective biological-morphological tumor response 
evaluable at radiological assessment after any type of therapy (LRT, chemotherapy, sorafenib). In case of 
no treatment, the possible increase of the tumor eventually represents its natural evolution, however not 
fully corresponding from a biological point of view to a tumor with a PD after a treatment. Moreover, in 
the great majority of cases, no-LRT cases presented a “fast-track” approach with short WT, thus 
impeding the “factor time” to select tumors with an effective tumor dimensional increase.  
We Added the following sentence in Material and Methods with the intent to explain this concept:  
“the decision to not consider no-LRT patients with a possible increase of the tumor burden before LT into 
the PD group derived from the consideration that these patients do not fully correspond from a biological 
point of view to patients with a tumor with a PD after a radiological treatment.” 
 
4) The authors state that “participating centers do not consider Milan Criteria as the limit”. Please be more 
precise. Which selection criteria were used? In addition, and on a similar note, the best ITT benefit was 
achieved in patients MC-OUT. Please be more precise in the description of the Milan out patients. How 
far can we go beyond Milan? Size? Number? 
 
ANSWER. We added in Table 1 information about the number of cases exceeding UCSFC, up-to-seven 
and Tokyo (“5+10 role”) criteria. Only 76 on 2103 (0.4%) patients contemporaneously exceeding all of 
these three criteria were eventually transplanted: all of these were transplanted before the introduction of 
MC or were transplanted in Padua centre, in which morphological aspects are no more used as selection 
tools but only biological features are commonly used for HCC selection.   
In Materials and Methods, we added the following sentence: 
“Despite different policies were used in the different centers, all the transplanted cases reported were 
within University of San Francisco California Criteria, Up-to-seven Criteria or Tokyo (“5+10 role”) 
Criteria: so, the dimensional upper limit observed in the present study was 6.5 cm of diameter in the 
target lesion and 10 nodules.” 
 
5) “160/246 (65.0%) cases dropped-out due to HCC progression”. Please specify why the other patients 
dropped-out. Did some patients improve/moved to another center? How were they handled? 
 
ANSWER. We added in Results the following sentence: 
“Looking more in detail the reasons of DO, 69 patients were excluded due to HCC progression (patient 
alive at the moment of DO). In 91 cases, a tumor-related death on WL was observed; 52 patients showed 
a liver disease-related death on WL, 25 moved to another center, and 9 were excluded due to poor 
compliance.” 
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6) How can an increased age be associated with an improved transplant survival (page 8)? This would 
mean that older patients should be favored compared to younger one. Please expend, and comment. 
ANSWER. We thank the reviewer for this comment. Actually, the data reported show that increased age 
was connected with an increased benefit, not an increased post-LT survival. In other terms, older patients 
obtained a higher benefit in being transplanted respect to being treated with other therapies respect to 
younger patients. However, when the cut-off value of ≥60 years of listing was used, a very small benefit of 
only 2 months was observed. So, the impact of such a result was neglectable and we decided not to 
describe it in discussion.  
 
7) The fact that the year of WL inscription has an impact on the transplant benefit suggests that 
practices/outcomes have changed over time, and that the proposed conclusions may not reflect current 
practice. Simply adding this variable in the multivariable model does not appear enough. Please use a 
more homogeneous population, covering a more restricted period. 
 
ANSWER. We thank again the reviewer for this comment. With the intent to appropriately correct our 
study in light of the suggestions of the Reviewers, we performed a complete statistical revision of our 
study with the help of an expert Statistician from Padua University.  
As suggested by the reviewer, we performed new multivariable models only evaluating patients listed 
after 01/01/2001 (n=1,802). 
As you can see in new supplementary tables 3 and 4, variables estimates obtained from multivariable 
models (i.e. for ITT LT survival, non-LT survival, and benefit) resulted very similar to that of the whole 
population (Table 2, suppl. Tables 1, 2). This sub-analysis gave us, therefore, a strong statistical 
demonstration that the introduction of the variable “period of LT” in all the multivariable models 
(n=2,103) of the first version of the paper effectively represented a guarantee of solid statistical 
approach.  
 
Reviewer: 2 
 
We really thank the reviewer for the positive comments. To better answer to his/her issues, we have 
performed a complete statistical revision of our study with the help of an expert Statistician from Padua 
University. 
 
 
1) Statistical methods must be checked by a statistician 
 
ANSWER. As suggested, we performed a complete statistical revision of our study with the help of an 
expert Statistician from Padua University. 
 
2) It is not clear which is the study-period: 1984-2015 (abstract) or 1987-2015 (Materials and Methods). 
 
ANSWER. We are sorry for this error. The first enlisted patient with the diagnosis of HCC was listed on 
February 12
th
, 1987. We have corrected the error in the abstract.  
 
Reviewer: 3 
 
We really thank the reviewer for the statistical suggestions and comments. To better answer to his/her 
issues, we have performed a complete statistical revision of our study with the help of an expert 
Statistician from Padua University. 
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1) Although the term "intention to treat" is well recognized in the clinical trial and statistical literature, it 
is not as common a term in observational designs. Please clarify in lay terms what is meant by ITT 
survival benefit during the introduction. 
 
ANSWER. The following sentence has been added in the Introduction section of the paper: 
“Moreover, transplant benefit values have been always evaluated from the moment of LT and not from 
the moment of WL inclusion. In the present study, the innovative concept of intention-to-treat (ITT) 
transplant benefit has been proposed. ITT survival is defined as the LT survival from the moment of 
patient enlistment and not from the day of LT, having been widely accepted in the LT community. The use 
of an ITT survival analysis allows the opportunity to analyze the results based on the initial treatment 
assignment and not on the treatment eventually received, thus avoiding various misleading artifacts and 
initial selection biases.” 
 
2) Methods: Please define the term MC-OUT (p 6 line 40). 
 
ANSWER. According to the suggestions already reported by Reviewer 1, we added in Table 1 information 
about the number of cases exceeding UCSFC, up-to-seven and Tokyo (“5+10 role”) criteria. Only 76 on 
2103 (0.4%) patients contemporaneously exceeding all of these three criteria were eventually 
transplanted: all of these were transplanted before the introduction of MC or were transplanted in Padua 
centre, in which morphological aspects are no more used as selection tools but only biological features 
are commonly used for HCC selection.   
In Materials and Methods, we added the following sentence: 
“Despite different policies were used in the different centers, all the transplanted cases reported were 
within University of San Francisco California Criteria, Up-to-seven Criteria or Tokyo (“5+10 role”) 
Criteria: so, the dimensional upper limit observed in the present study was 6.5 cm of diameter in the 
target lesion and 10 nodules.” 
 
3) The MESIAH score was used to simulate time to death in patients that were censored by LT.  The 
simulated additional time they would have lived in absence of LT was then summed with their wl time.  
Given that this was essentially a missing data problem, there is uncertainty in this value from the 
imputation.  Rather than giving this imputed value the same weight as an actual observed value, the 
imputation process should account for this uncertainty.  Multiple imputation would be one way to account 
for this. 
 
ANSWER. We understand the perplexities of the reviewer concerning our non-LT survival model. 
However, using a real HCC population waiting LT to predict long-term survival represents a great (and 
probably not solvable) statistical problem because the high proportion of patients censored for LT at a 
very low median time from listing as underlined in detail in the supplementary text.  
Also the expert statistician from Padua University now reviewing our data confirmed that this peculiarity 
of waiting list populations cannot be resolved as a missing data imputation problem for some main 
reasons: 
1. of the cohort of 2,103 patients included, 1,894 had the LT at a median time of 5.2 months from 
listing (90% censoring); 
2. the reason for censoring is informative rather than not informative, while missing data are 
supposed to be at random. 
For these reasons, we afforded the problem using the best predictive survival model for HCC patients 
(i.e. the MESIAH score) simulating the survival of patients if had they not been transplanted. 
We sincerely hope that the reviewer could accept this original but also unavoidably biased 
methodological aspect of this study. The aim of this study is not to give extremely precise estimations of 
LT survival benefit, but only to obtain a qualitative stratification of the HCC population in different 
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subgroups (i.e. no, small, moderate, high benefit) in order to help clinicians in selecting HCC patients for 
LT according to the innovative ITT transplant benefit principle. 
 
4) Is the multivariate least squares regression a linear regression? 
 
ANSWER. Yes, it was. 
 
5) Please describe the steps for determining the significant factors in the multivariable analysis of survival 
benefit. Provide clarity on the census of variables considered for the multivariable model and be specific 
as to how the variables were selected for inclusion. (E.g. where they based on a univariate screening 
process followed by inclusion of all significant factors in the model or some other selection procedure?). 
 
ANSWER. We really thank the reviewer for this comment underlying a missing aspect of our original 
methods section. In the original paper, in fact, this explanation was only written below supplementary 
tables. We now specified also in the methods that: 
“In all the multivariable survival models, all variables with p<0.1 at univariate model were included. In 
the final model only variables showing a significant impact on survival at the first multivariable model 
were maintained.” 
 
6) Specify the units of survival benefit in table 2. 
 
ANSWER. We now specified that the units of survival benefit were months. 
 
7) Please describe what the d-value is and how it's calculated in the methods. 
 
ANSWER. Again, we thank the reviewer for this comment giving us the possibility to better explain our 
methods. We now specified that: 
“Since p-values can be biased from population size, results of survival benefit estimations in covariates 
subgroups were reported as effect size. Effect size is a standard measure that can be calculated from any 
number of statistical outputs. One type of effect size, the standardized mean effect, expresses the mean 
difference between two groups in standard deviation units. Typically, it is reported as Cohen's d, or 
simply referred to as d-value.” 
A new reference was added accordingly: Burnand B, Kernan WN, Feinstein AR. Indexes and boundaries 
for "quantitative significance" in statistical decisions. J Clin Epidemiol 1990; 43: 1273–84. 
 
8) Can confidence intervals be added to the effect size (d-values) estimates in table 3? 
 
ANSWER. As requested, we added 95% confidence intervals in Table 3. 
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TABLES 
Table 1. Patient- and tumor-related characteristics in the EURHECALT study population. 
 
 
Variables 
Study group (n=2103) 
Median (IQR) or n (%) 
 
Period of WL inscription (1987-2000 vs. 2001-2015) 301/1802 (14·3/85·7) 
WT days 
    ≥120 days 
137 (57-284) 
963 (45·8) 
Male gender 1763 (83·8) 
Recipient age at WL inscription (years) 
    ≥60 years 
56·8 (49·7-62·0) 
731 (34·8) 
Cause of underlying cirrhosis (*) 
    HCV 
    HBV 
    Alcohol 
 
1001 (47·6) 
391 (18·6) 
631 (30·0) 
Laboratory MELD at LT or DO 
    MELD ≤13 
12 (9-16) 
1395 (66·3) 
Laboratory albumin (g/dl) at LT or DO 4·0 (3·8-4·0) 
HCC at WL inscription 
    Major lesion diameter (cm)  
    Number of lesions  
    MC-OUT status 
 
3·0 (2·0-4·0) 
2 (1-3) 
636 (30·2) 
Last radiological HCC assessment 
    Major lesion diameter (cm) 
    Number of lesions 
    MC-OUT status 
    University of San Francisco California Criteria status 
    Up-to-seven Criteria status 
    Tokyo Criteria (“5+10 role”) status 
 
2·0 (0·0-3·0) 
1 (1-3) 
476 (22·6) 
349 (16·6) 
253 (12·0) 
114 (5·4) 
LRT (**) 
   Total number of procedures 
   Complete response  
   Progressive disease 
1754 (83·4) 
2 (1-3) 
380 (18·1) 
491 (23·3) 
AFP 
   At listing (ng/mL) § 
   Last available AFP (ng/mL) 
   ≥1000 ng/mL 
   Slope ≥15 ng/mL/month § 
 
10·0 (4·8-37·3) 
9·7 (4·4-34·9) 
63 (3·0) 
228 (12·6) 
DO 
    HCC-related DO 
    Death during WT 
246 (11·7) 
160 (7·6) 
143 (6·8) 
Recurrence (***) 
    Within 1 year after LT 
    Within 2 years after LT 
    Within 3 years after LT 
    Within 5 years after LT 
242/1504 (16·1) 
76/1504 (5·1) 
138/1504 (9·2) 
172/1504 (11·4) 
213/1504 (14·2) 
 
(*) multiple causes in the same patient: HCV + alcohol=101; HCV + HBV=29; HBV + alcohol=22; HCV + 
HBV + alcohol=6; alcohol + other=6; HCV + other cause=5; alcohol + NASH=5; HCV + alcohol + other 
cause=3; HBV + other cause=3; HCV + HBV + alcohol + NASH=1.  
(**) percentages calculated only on patients undergoing LRT. 
(***) percentages calculated only on transplanted patients with FU > 1 year. 
§ medians, IQR and percentages calculated on 1804 (85·8%) cases with available data. 
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Abbreviations: WT, waiting time, IQR, interquartile ranges; WL, waiting list; HCV, hepatitis C virus; HBV, 
hepatitis B virus; NASH, non-alcoholic steato-hepatitis; MELD, model for end-stage liver disease; LT, liver 
transplantation; DO, drop-out HCC, hepatocellular cancer; MC, Milan Criteria; LRT, loco-regional 
treatment; AFP, alpha-fetoprotein; FU, follow-up. 
 
 
Table 2. Multivariate least square regression evaluating significant predictors of ITT transplant 
benefit. 
 
 
Variables 
Multivariable model 
Coefficient ± SE 
(months) 
 
p value 
Constant -14·7 ± 2·7 <0·0001 
WL inscription before 2001 -25·3 ± 1·0  <0·0001 
Age at listing (per year) / 10 1·3 ± 0·4 0·0006 
MELD at LT or DO 1·1 ± 0·1  <0·0001 
WT (per month) 0·1 ± 0·03  0·001 
mRECIST progression disease -36·8 ± 0·9 <0·0001 
Last radiological HCC assessment 
    Major lesion diameter (cm) 
    Number of lesions 
 
10·9 ± 0·4  
6·5 ± 0·3 
 
<0·0001 
<0·0001 
Last available logAFP  -3·4 ± 0·2  <0·0001 
 
The constant term in the final model represents the estimated ITT 
survival benefit of LT in the mean patient. The covariates effects 
for the estimated ITT benefit are assumed to be additional to the 
constant term. 
Abbreviations: SE, standard error; WL, waiting list; MELD, 
model for end-stage liver disease; LT, liver transplantation; DO, 
drop-out; WT, waiting time; mRECIST, modified response 
evaluation criteria in solid tumors; HCC, hepatocellular cancer; 
AFP, alpha-fetoprotein. 
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Table 3. ITT transplant benefit estimations in months in different subgroups. 
 
 
Variables 
Benefit in months 
(n of patients) 
Benefit in months 
(n of patients) 
 
D value between 
Groups (95% CI) 
 
Difference 
 No Yes 
WT ≥120 days 25·5 (1140) 24·0 (963) 0·06 (0·01-0·13) Very small 
Age at listing ≥60 years 25·5 (1372) 23·6 (731) 0·07 (0·02-0·16) Very small 
Last AFP ≥ 20 ng/mL 27·0 (1439) 20·3 (664) 0·26 (0·17-0·36) Small 
MC-IN at LT or DO 34·5 (496) 22·8 (1607) 0·47 (0·37-0·57) Moderate* 
WL inscription before 2001 27·3 (1802) 10·4 (301) 0·69 (0·57-0·81) Large§ 
Last AFP ≥1000 ng/mL 25·4 (2040) 6·8 (63) 0·74 (0·49-0·99) Large* 
mRECIST progression disease 29·2 (1612) 10·6 (491) 0·78 (0·67-0·88) Large* 
MELD at LT or DO ≤13 39·1 (708) 19·8 (1395) 0·81 (0·73-0·90) Large* 
mRECIST complete response 28·7 (1723) 7·2 (380) 0·90 (0·79-1·01) Large* 
Benefit Groups (*) 
Group Benefit in months n of patients (%)  
No benefit 0 405 (19·2) 3-4 negative factors 
Small benefit 20 897 (42·7) 2 negative factors  
Moderate benefit 40 693 (33·0) 1 negative factor 
Large benefit 60 108 (5·1) No negative factors 
 
Continuous variables in Table 4 were dichotomized using relevant cut-off values used in the literature 
(5,6,11,12). 
Results are reported as means; D-value (effect size) values <0·1 indicate very small differences; between 0·1 
and 0·3 and between 0·3 and 0·5 indicate small and moderate differences, respectively, and > 0·5 indicate 
large differences. 
(*) Four risk factors were considered for constructing the benefit groups: MELD ≤13; MC-IN; mRECIST 
progression disease or complete response; AFP ≥1000 ng/mL. Benefit values in the groups were rounded to the 
nearest whole number.  
(§) WL inscription before or after 2001 was not considered in the final group stratification because the period 
of WL inscription showed a very poor effect on survival benefit estimates (supplementary Tables 3-4) and it 
was not considered useful for the evaluation of the benefit in patients enlisted now.   
Abbreviations: CI, confidence interval; WL, waiting list; WT, waiting time; AFP, alpha-fetoprotein; MC, 
Milan Criteria; LT, liver transplantation; DO, drop-out; MELD, model for end stage liver disease; mRECIST, 
modified response evaluation criteria in solid tumors.  
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Supplementary Data 1 
The statistical design of this study included three main steps: a) the development of an ITT LT 
survival model; b) the development of a non-LT survival model and; c) the individual prediction of 
the ITT survival benefit of LT defined as the difference between the median ITT survival with LT 
(based on the first model) and median survival without LT (based on the second model) calculated 
for each enrolled patient. 
 
Step a) ITT LT survival model 
Length of follow-up and survival were expressed as medians (IQR). Overall survival was calculated 
from date of WL inclusion until death from any cause (before or after LT) or latest follow up. HCC 
patients dropping-out from the WL were followed until death or last follow-up. Survival curves 
were estimated using the Kaplan Meier method, whereas the statistical significance between 
survival curves was tested by the Log Rank test.  
Several survival models (the semi-parametric Cox model, and parametric exponential, log-normal, 
Weibull, and log-logistic models) were tested; since the aim of this study was to develop a model 
able to give precise estimation of individual median survival after WL inclusion, it was decided to 
use an accelerated failure time parametric model. Among the different models available (gamma, 
log-logistic, lognormal), the log-logistic model was selected since it showed the lowest value of 
Akaike Information Criterion (AIC) at final multivariable model. 
Finally, this model was applied to predict ITT median survival with LT of each enrolled patient. 
 
Step b) Non-LT survival model 
The prediction of non-LT survival using a WL population is controversial. The main statistical 
problem is that WL patients have relatively few failure events (death before LT) since the majority 
of them are censored by LT. Censoring related to LT, however, is an informative or dependent 
censoring since it depends on prioritization criteria used in each center.
1,2
 Moreover, median WT of 
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HCC patients is relatively short, usually less than one year, thus prediction of long-term survival of 
these patients may be inaccurate.
3
  
Some statistical techniques such as competing risk analysis,
1,4
 or inverse probability censoring 
weight have been used to overcome these problems.
2
 However, these methods seem still insufficient 
to resolve all the biases related to the complexity of WL dynamics and further corrections, 
sometime quite arbitrary, are necessary.
4,5 
Since it was aimed to predict median long-term survival of enrolled HCC patients (n=2103) without 
LT, these statistical solutions were judged unsuitable for the present analysis. 
The Model to Estimate the Survival In Ambulatory patients with HCC (MESIAH) has been recently 
developed with the specific aim to predict individual HCC patient survival.
6
 This model, proven to 
have a higher prognostic ability than that of available HCC prognostic systems, has been externally 
validated both in western and eastern countries.
7,8
 
More importantly, the authors of this score provided a simple formula to translate the MESIAH 
score in individual survival predictions. Using patient characteristics at the last evaluation before 
LT or DO, we used the MESIAH score to simulate the median time to death that patients censored 
by LT would have had in the absence of LT. So, time to death of enrolled patients censored by LT 
(n=1857) was calculated as the sum of their true WL time (from listing to LT) and the simulated 
additional time they would have lived in the absence of LT. 
This simulated time to death was therefore used to perform a second log-logistic parametric survival 
model to find significant predictors of non-LT survival.   
Finally, we used this second model to predict non-LT median survival of each enrolled patient. 
 
Step c) ITT transplant benefit model 
The ITT LT and the non-LT survival log-logistic models generated two median survival predictions 
for each enrolled patient. The ITT survival benefit of LT was, therefore, calculated for each patient 
as the difference between ITT LT median and the non-LT median survival estimations. All 
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estimations were capped at 120 months, since this time horizon represents the ideal balance 
between utility and urgency allocation principles.
9
 A multivariate least square regression was finally 
used to find significant predictors of ITT LT benefit among studied variables.
10,11
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Supplementary Table 1 
Multivariate log-logistic parametric survival analysis evaluating significant predictors of ITT LT 
survival. 
 
 
 
Variables 
Univariate analysis 
First multivariable 
model (*) 
Final multivariable 
model (**) 
Coefficient ± SE,  
p value 
 
Coefficient ± SE,  
p value 
 
Coefficient ± SE,  
p value 
 
WL inscription before 2001 -0·45 ± 0·14 0·002 -0·59±0·15 <0·0001 -0·61±0·14 <0·0001 
Male gender 0·14±0·14 0·35 - - - - 
Age at listing (per year) / 10 -0·26±0·06  <0·0001 -0·25±0·06 <0·0001 -0·25±0·06  <0·0001 
HCV positivity -0·17±0·11  0·12 - - - - 
HBV positivity 0·07±0·14  0·60 - - - - 
Alcohol abuse history 0·10±0·12  0·39 - - - - 
MELD at LT or DO -0·07±0·01  <0·0001 -0·17±0·09  0·07 -0·07±0·01  <0·0001 
Albumin at LT or DO 0·75±0·14  <0·0001 -1·17±1·10  0·28 - - 
WT (per month) 0·02±0·01  0·0001 0·02±0·01  <0·0001 0·02±0·01  <0·0001 
HCC at WL inscription 
    Major lesion diameter (cm) 
    Number of lesions  
 
-0·09±0·04  
0·05±0·03  
 
0·01 
0·08 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
No LRT -0·08±0·14  0·59 - - - - 
Total number of LRT -0·01±0·02  0·92 - - - - 
mRECIST complete response 0·35±0·15  0·02 -0·06±0·18  0·76 - - 
mRECIST progression disease -1·07±0·12  <0·0001 -1·13±0·13  <0·0001 -1·14±0·13  <0·0001 
Last radiological HCC assessment 
    Major lesion diameter (cm) 
    Number of lesions 
 
-0·27±0·05  
-0·09±0·04  
 
<·0001 
0·02 
 
-0·06±0·07  
0·10±0·05  
 
0·38 
0·05 
 
- 
0·08±0·04  
 
- 
0·05 
AFP 
   LogAFP at listing  
   Last available logAFP  
  Slope ≥ 15 ng/mL/month 
 
-0·12±0·03  
-0·22±0·03  
-0·62±0·08  
 
0·0004 
<0·0001 
<0·0001 
 
- 
-0·17±0·03  
- 
 
- 
<0·0001 
- 
 
- 
-0·18±0·03  
- 
 
- 
<0·0001 
- 
 
The negative sign indicates a negative impact on survival. 
(*) In the first multivariable model all variables with p<0·1 at univariate model were included. The model showing the 
lowest AIC value was finally chosen. 
(**) In the final model only variables showing a significant impact on survival at the first multivariable model were 
maintained. The model showing the lowest AIC value was chosen. 
Abbreviations: SE, standard error; WL, waiting list; HCV, hepatitis C virus; HBV, hepatitis B virus; MELD, model for end-
stage liver disease; LT, liver transplantation; DO, drop-out; WT, waiting time; HCC, hepatocellular cancer; LRT, loco-
regional therapies; mRECIST, modified response evaluation criteria in solid tumors; AFP, alpha-fetoprotein.  
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Supplementary Table 2 
Multivariate Log-logistic parametric survival analysis evaluating significant predictors of non-LT-
survival. 
 
 
 
Variables 
Univariate analysis 
First multivariable 
model (*) 
Final multivariable 
model (**) 
Coefficient ± SE,  
p value 
 
Coefficient ± SE,  
p value 
 
Coefficient ± SE,  
p value 
 
WL inscription before 2001 -0·01 ± 0·05 0·89 -0·03±0·02 0·25 0·05±0·02 0·01 
Male gender 0·04±0·14 0·35 - - - - 
Age at listing (per year) / 10 -0·13±0·02  <0·0001 -0·17±0·01  <0·0001 -0·17±0·01  <0·0001 
HCV positivity -0·01±0·04  1·00 - - - - 
HBV positivity 0·02±0·04  0·59 - - - - 
Alcol abuse history 0·02±0·01  0·59 - - - - 
MELD at LT or DO -0·12±0·01  <0·0001 -0·11±0·01  <0·0001 -0·11±0·01  <0·0001 
Albumin at LT or DO 1·36±0·05  <0·0001 0·05±0·24  0·83 - - 
WT (per month) 0·01±0·01  <0·0001 0·01±0·01  <0·0001 0·01±0·01  <0·0001 
HCC at WL inscription 
    Major lesion diameter (cm) 
    Number of lesions  
 
-0·07±0·01  
-0·13±0·01  
 
<0·0001 
<0·0001 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
No LRT -0·24±0·05  <0·0001 -0·05±0·02  0·02 - - 
Total number of LRT 0·01±0·01  0·63 - - - - 
mRECIST complete response 0·55±0·04  <0·0001 -0·16±0·03  <0·0001 - - 
mRECIST progression disease -0·67±0·04  <0·0001 -0·19±0·03  <0·0001 -0·32±0·02 <0·0001 
Last radiological HCC assessment 
    Major lesion diameter (cm) 
    Number of lesions 
 
-0·35±0·01  
-0·22±0·01  
 
<0·0001 
<0·0001 
 
-0·22±0·01  
-0·10±0·01  
 
<0·0001 
<0·0001 
 
-0·20±0·01  
-0·06±0·01  
 
<0·0001 
<0·0001 
AFP 
   LogAFP at listing  
   Last available logAFP  
  Slope ≥ 15 ng/mL/month 
 
-0·06±0·01  
-0·13±0·01  
-0·35±0·03  
 
<0·0001 
<0·0001 
<0·0001 
 
- 
-0·07±0·01  
- 
 
- 
<0·0001 
- 
 
- 
-0·07±0·01  
- 
 
- 
<0·0001 
- 
 
The negative sign indicates a negative impact on survival. 
(*) In the first multivariable model all variables with p<0·1 at univariate model were included. The model showing the lowest 
AIC value was finally chosen. WL inscription was maintained in the model for homogeneity with the ITT-LT survival model. 
(**) In the final model only variables showing a significant impact on survival at the first multivariable model were 
maintained. The model showing the lowest AIC value was finally chosen. 
Abbreviations: SE, standard error; WL, waiting list; HCV, hepatitis C virus; HBV, hepatitis B virus; MELD, model for end-
stage liver disease; LT, liver transplantation; DO, drop-out; WT, waiting time; HCC, hepatocellular cancer; LRT, loco-
regional therapies; mRECIST, modified response evaluation criteria in solid tumors; AFP, alpha-fetoprotein. 
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Supplementary Table 3 
Multivariate log-logistic parametric survival analyses evaluating significant predictors of ITT LT 
and non-LT - survival in patients listed after 01/01/2001 (n=1802). 
 
 
 
 
Variables 
ITT LT multivariable 
model (*) 
Non-LT multivariable 
model (**) 
Coefficient ± SE,  
p value 
 
Coefficient ± SE,  
p value 
 
Age at listing (per year) / 10 -0·21±0·07 <0·0001 -0·17±0·01  <0·0001 
MELD at LT or DO -0·08±0·01  <0·0001 -0·11±0·01  <0·0001 
WT (per month) 0·02±0·01  0·0017 0·01±0·01  <0·0001 
mRECIST progression disease -1·26±0·14  <0·0001 -0·47±0·02  <0·0001 
Last radiological HCC assessment 
    Major lesion diameter (cm) 
    Number of lesions 
 
- 
0·13±0·04  
 
- 
0·0034 
 
-0·19±0·01 
-0·04±0·01  
 
<0·0001 
<0·0001 
Last available logAFP 
-0·19±0·03  
 
<0·0001 
 
-0·08±0·01  
 
 
<0·0001 
 
 
The negative sign indicates a negative impact on survival. 
Abbreviations: SE, standard error; WL, waiting list; HCV, hepatitis C virus; HBV, hepatitis B 
virus; MELD, model for end-stage liver disease; LT, liver transplantation; DO, drop-out; WT, 
waiting time; HCC, hepatocellular cancer; LRT, loco-regional therapies; mRECIST, modified 
response evaluation criteria in solid tumors; AFP, alpha-fetoprotein. 
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Supplementary Table 4 
 
Multivariate least square regression evaluating significant predictors of ITT transplant benefit in 
patients listed after 01/01/2001 (n=1802). 
 
 
 
Variables 
Multivariable model 
Coefficient ± SE   
 
p value 
Constant -26·7 ± 3·0 <0·0001 
Age at listing (per year) / 10 3·0 ± 0·4 <0·0001 
MELD at LT or DO 1·1 ± 0·1  <0·0001 
WT (per month) 0·1 ± 0·04  0·001 
mRECIST progression disease -37·6 ± 1·0 <0·0001 
Last radiological HCC assessment 
    Major lesion diameter (cm) 
    Number of lesions 
 
11·1 ± 0·5  
6·6 ± 0·4 
 
<0·0001 
<0·0001 
Last available logAFP  -2·8 ± 0·2  <0·0001 
 
The constant term in the final model represents the estimated ITT 
survival benefit of LT in the mean patient. The covariates effects 
for the estimated ITT benefit are assumed to be additional to the 
constant term. 
Abbreviations: SE, standard error; WL, waiting list; MELD, 
model for end-stage liver disease; LT, liver transplantation; DO, 
drop-out; WT, waiting time; mRECIST, modified response 
evaluation criteria in solid tumors; HCC, hepatocellular cancer; 
AFP, alpha-fetoprotein. 
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